In this story we learn of one of the most important recent advances in the treatment of ovarian cancer. In a randomized trial, intraperitoneal (IP) chemotherapy extended survival by 16 months compared to standard chemotherapy in women with stage 3 ovarian cancer. It is such an important finding that, in a rare move, the National Cancer Institute issued a statement calling for a change in clinical practice. This AP story adequately represents the prevalence and seriousness of ovarian cancer. The story adequately presents the alternative treatment option (intravenous chemotherapy) and the advantages and disadvantages of the new approach. The clinical evidence is presented accurately (although they did not mention that this was a randomized trial) and the benefits of treatment are presented for both intravenous and intraperitoneal chemotherapy. The story is especially strong in frankly portraying the harms and side effects of treatment, which were so bad that most women in the study were not able to complete the full course of treatment. The author does present a second opinion from an independent source. However, the story did not explain whether or not this treatment is novel, how widely available it is (and, by extension, how many practicitioners are experienced administering the treatment), and the costs or cost-effectiveness. Another major limitation of the story is that they did not attempt to place this treatment within the context of the overall picture of ovarian cancer. This study involved women with stage 3 ovarian cancer. What percentage of ovarian cases does that represent? What does that mean for women who are more/less advanced? The story leaves the reader thinking this treatment would be used for any woman with ovarian cancer, when in reality, we don’t know if it could help women who are more or less advanced than the study population. Presumably it would not be appropriate for early stage disease given the toxicity of the treatment, but what about later stages (which represent a large portion of ovarian cancer patients)?
No mention of costs
The story quantifies the benefits in terms of
survival for both intravenous and intraperitoneal chemotherapy.
The story gives us balanced information on harms, including the
very serious side effects which led to less than half the study population adhering to the full course of chemo.
The story accurately represents the nature of the clinical evidence, that this was a controlled trial with 415
women. It should have been more clear that it was a randomized trial.
The story accurately represents the prevalence of ovarian cancer and the
survival.
Independent
source is quoted.
The author does mention intravenous chemotherapy as the alternative and explains
the advantages and disadvantages of the new approach.
Clearly this treatment is available in the U.S., but it’s not clear how widely available it is
and how many oncologists have experience using it.
The story does not mention
if the treatment is new or not.
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like